Search

Ion Beam Applications

Atidarymo kaina

10.86 -0.18

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.8

Max

11.08

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-10M

Pardavimai

206M

P/E

Sektoriaus vid.

41.111

63.778

Dividendų pajamingumas

1.56

Pelno marža

-4.99

Darbuotojai

1,943

EBITDA

-372K

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.56%

2.39%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

342M

Ankstesnė atidarymo kaina

11.04

Ankstesnė uždarymo kaina

10.86

Ion Beam Applications Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2024-09-11 06:28; UTC

Įsigijimai, susijungimai, perėmimai

EQT Leads $102.5 Million Series A Funding Round in Belgian Radioisotope Producer PanTera

Ion Beam Applications Prognozė

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ion Beam Applications

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.